OVP E 48 95 AUG 0 4 2006 U.55 a

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 vatent and Trademark Office; U.S. DEPARTMENT OF COMMERCE information unless it contains a valid OMB control number.

| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Filing First N Art Ur | lamed Inventor Abraham NUDELMAN et al |
|---|--|
| STATEMENT BY APPLICANT (use as many sheets as necessary) An Un | lamed Inventor Abraham NUDELMAN et al |
| (use as many sheets as necessary) Art Ur | |
| | nit 1624 |
| | |
| | ner Name COLEMAN, Brenda Libby |
| Sheet 1 of 2 Attorn | ey Docket Number 27755 |
| U.S. PATENT DOCU | MENTS |
| Examiner Cite Document Number Publication Date | Name of Patentee or Pages, Columns, Lines, Where Applicant of Cited Document Relevant Passages or Relevant |
| Number-Kind Code ² (if known) | Figures Appear |
| BC 1 US-3,966,930 06-29-1976 | Buus et al. 514 225.8 |
| BC 2 US-5,994,392 11-30-1999 | Shashoua et al. 514 437 |
| BC 3 US-5,525,727 06-11-1996 . | Bodor et al. 546 39 |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| FORM ON PARTITION | |
| FOREIGN PATENT DO | |
| initials* No. 1 Foreign Patent Documents Publication Date | Name of Patentee or Pages, Columns, Lines, Where Relevant Passages |
| 101001000 | Applicant of Cited Document or Relevant Figures Appear |
| Country Code ³ Number ⁴ Kind Code ³ (if known) | Or recevant rightes Appear |
| Country Code ³ Number ⁴ Kind Code ⁵ (if known) | |
| Country Code ³ Number ⁴ Kind Code ³ (if known) | Gil-Ad et al. Nudelman et al. |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.usplo.gov or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English tanguage Translation is attached.

Date

Considered

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Examiner

Signature

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE formation unless it contains a valid OMB control number.

| | Sut | stitute for form 1449A/PTO | l | Complete i | | 41 | |
|--|--|---|---|--|---------|----------------|--|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | Application Number 10/80 | | | | |
| | | | Filing Date | March 2 | 5, 2004 | | |
| | | | First Named Inventor Abi | | 1 | | |
| | (| (use as many sheets as necessary) | | | NUDEL | MAN et al | |
| | | (,, , | | Group Art Unit | 1624 | | |
| | | | | | | | |
| • | | | | Examiner Name | | AN, Brenda | |
| | | | | | Libby | | |
| Sheet | 2 | of | 3 | Attorney Docket Number | 27755 | | |
| | | OTHER PRIOR ART – NON PA | TENT LITERA | TURE DOCUMENTS | | | |
| Examiner | Cite | Include name of the author (in CAPITAL LET | | | | | |
| Initials | No.1 | item (book, magazine, journal, serial symposiu | m, catalog, etc.) date or country where pu | e, page(s), volume-issue numb hlished | er(s), | T ² | |
| 0.0 | 6 | Nordenberg et al. "Effects of Psychotro | | | | | |
| BC | | Differentiation", Biochemical Pharmace | | | | | |
| Re | 7 | Fingl et al. "General Principles", The Pharmacological Basis of Therapeutics, | | | | | |
| BC | | Chap.1: 1-46, 1975. | | | | | |
| BC | 8 | Budavari et al. " The Merck Index", Merck & Co., USA, 12th Ed., 1996. P.THER-8, | | | | | |
| | <u> </u> | First Col., 6th Line From the Bottom, 2nd Col., Line 13. | | | | | |
| BC | 9 | Budavari et al. "The Merck Index", Merck & Co., USA, 12th Ed, 1996. P.1260, § 1. | | | | | |
| BC | 10 | Budarari et al. "The Merck Index", Merck & Co., USA, 12th Ed., 1996. P.1246, Last §. | | | | | |
| | 11 | Scriba et al "Anticonvulsant Activity of | Phenytoin-Lipi | d Conjugates. A New Cl | ass of | | |
| BC | | Phenytoin Prodrugs" - Journal of Pharmaceutical Pharmacology, 47: 197-203, 1996. | | | | | |
| · | 12 | Scriba "Phenytoin-Lipid Conjugates as | | | | | |
| BC | | 1993. | | | | | |
| BC | 13 | Capasso et al. "Anticonvulsive Activity of A New GABA Mimetic Drug", European Neuropsychopharmacology, 7: 57-63, 1997. Geyer et al. "Animal Behavior Models of the Mechanisms Underlying Antipsychotic | | | | | |
| | | | | | | | |
| a - | 14 | | | | | | |
| BC | | Atypicality", Progress in Neuro-Psychopharmacology & Biological Psychiatry, 27: 1071-1079, 2003. | | | | | |
| () A | 15 Köpf-Maier et al. "An Organoid Culture Assay (OCA) for Determining the Drug | | | | | | |
| BC | | Sensitivity of human Tumors", Int. J. Cancer, 51: 99-107, 1992. | | | | | |
| | -16 | Lloyd et al. "The Potential Use of GAB | A Agonists in P | sychiatric Disorders: | | | |
| BC | | Evidence From Studies With Progabide in Animal Models and Clinical Trials", | | | | | |
| | | Pharmacology, Biochemistry & Behavior, 18: 957-966, 1983. | | | | | |
| BC | 17 | McCaffrey et al. "A Rapid Fluorometric | | | | | |
| | | Density and Proliferation In Vitro", In Vitro Cellular Development Biology, 24(3): | | | | | |
| | 18 | 247-252, 1988. Abstract. Nicoletti et al. "A Rapid and Simple Me | athed for Messu | ring Thumpouts Assets | nia bu | | |
| BC | 10 | Propidium Iodide Staining and Flow Cy | | | sis by | | |
| | | Methods, 139: 271-279, 1991. | romeny, Journ | iai or miniunological | | | |
| | 19 | Ouadri et al. "Effects of Centrally Actir | ng Drugs on Sen | um Prolactin Levels in R | hesus | | |
| BC | " | Quadri et al. "Effects of Centrally Acting Drugs on Serum Prolactin Levels in Rhesus Monkeys", Neuroendocrinology, 27(3-4): 136-147, 1978. Abstract. | | | | | |
| | 1 | | ., , | | -+ | | |

| Signature | Branda | Coleman | Considered | Jan. 29 2007 |
|-----------|--------|---------|------------|--------------|
| | | | | |

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | Act of 1995, no persons are required to respond | to a concerion of intomation | Complete | | |
|---|--|---|------------------------------|---------------------------------------|--------|----------------|
| | Su | bstitute for form 1449A/PTO | | Application Number | 10/808 | ,541 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | Filing Date | March 25, 2004 Abraham | | |
| | | | First Named Inventor | | | |
| | | | 1 | | NUDE | LMAN et al |
| | | | | Group Art Unit | 1624 | |
| | | | | Examiner Name | COLE | MAN, Brenda |
| | | · | | . Daning Hame | Libby | virat, Divida |
| | 1. | | | | | |
| Sheet | 3 | of | 3 | Attorney Docket Number | 27755 | |
| | | | | RATURE DOCUMENTS | | |
| Examiner nitials | Cite No. ¹ | Include name of the author (in CAPIT item (book, magazine, journal, serial | FAL LETTERS), title of the | e article (when appropriate), title (| of the | T ² |
| nitiais | | publisher, | , city and/or country where | published. | C.(3), | 1- |
| 00 | 20 | Pouzet et al. "Effects of the 5-HT7 Receptor Antagonist SB-258741 in Animal | | | | |
| BC | | Models for Schizophrenia", Pharmacology, Biochemistry and Behavior, 71: 655-665, | | | | |
| · | 21 | 2002. | · | - II CL - E | • | |
| 00 | 21 | Shalitin et al. "The Effect of Angiotensin II on Myosin Heavy Chain Expression in Cultured Myocardial Cells", In Vitro Cellular Development Biology - Animal, 32: | | | | - |
| BC | | 573-578, 1996. | | | | |
| BC | 22 | Toth "A Novel Chemical Approach to Drug Delivery: Lipidic Amino A | | | i | |
| • | | Conjugates", Journal of Drug Targeting, 2: 217-239, 1994. | | | | |
| BC | 23 | Wolffe "Transcriptional Control. Sinful Repression", Nature, 387: 16017, 1997. | | | | |
| n. | 24 | Worms et al. "Dopamine-Like A | Activities of An Amin | opyridazinde Derivative, C | CM | |
| BC | | 30366: A Behavioural Study", N 334: 246-252, 1986. | Naunyn-Schmiedeberg | g's Archives of Pharmacolo | pgy, | • |
| | | 334. 240-232, 1980. | | | | |
| | | | | | | |
| | 1 | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | - | | | | | |
| | | | | | | |
| | + | - | | | | |
| | + | | | | | |
| | | | | i i i i i i i i i i i i i i i i i i i | | |

| Signature | Brenda | Coloman | Considered | Jan. 29 200 |
|-----------|--------|---------|------------|-------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.